Cargando…

Mutual activation of glutamatergic mGlu(4) and muscarinic M(4) receptors reverses schizophrenia-related changes in rodents

RATIONALE: Metabotropic glutamate receptors and muscarinic M(4) receptors have been proposed as novel targets for various brain disorders, including schizophrenia. Both receptors are coupled to G(o/i) proteins and are expressed in brain circuits that are important in schizophrenia. Therefore, their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cieślik, Paulina, Woźniak, Monika, Rook, Jerri M., Tantawy, Mohammed N., Conn, P. Jeffrey, Acher, Francine, Tokarski, Krzysztof, Kusek, Magdalena, Pilc, Andrzej, Wierońska, Joanna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182605/ https://www.ncbi.nlm.nih.gov/pubmed/30054675 http://dx.doi.org/10.1007/s00213-018-4980-y

Ejemplares similares

Involvement of GABA(B) Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu(4) Receptor, LSP4-2022
por: Woźniak, Monika, et al.
Publicado: (2016)

Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia
por: Wierońska, Joanna M., et al.
Publicado: (2011)

The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT(1A) signalling
por: Wierońska, Joanna M., et al.
Publicado: (2013)

Structural insights into dimerization and activation of the mGlu2–mGlu3 and mGlu2–mGlu4 heterodimers
por: Wang, Xinwei, et al.
Publicado: (2023)

Negative Allosteric Modulators of mGlu(7) Receptor as Putative Antipsychotic Drugs
por: Cieślik, Paulina, et al.
Publicado: (2018)

Activation of Metabotropic Glutamate Receptor (mGlu(2)) and Muscarinic Receptors (M(1), M(4), and M(5)), Alone or in Combination, and Its Impact on the Acquisition and Retention of Learning in the Morris Water Maze, NMDA Expression and cGMP Synthesis
por: Wierońska, Joanna M., et al.
Publicado: (2023)

On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
por: Pałucha-Poniewiera, Agnieszka, et al.
Publicado: (2010)

Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia
por: Foster, Daniel J, et al.
Publicado: (2014)

New 1,2,4-oxadiazole derivatives with positive mGlu(4) receptor modulation activity and antipsychotic-like properties
por: Stankiewicz, Anna, et al.
Publicado: (2021)

Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network
por: Tassin, Valériane, et al.
Publicado: (2016)

Design and Synthesis of New Quinazolin-4-one Derivatives with Negative mGlu(7) Receptor Modulation Activity and Antipsychotic-Like Properties
por: Kaczorowska, Katarzyna, et al.
Publicado: (2023)

Neurobiological Insights from mGlu Receptor Allosteric Modulation
por: O’Brien, Daniel E, et al.
Publicado: (2015)

mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists
por: Zammataro, Magda, et al.
Publicado: (2011)

mGlu(5) Positive Allosteric Modulators Facilitate Long-Term Potentiation via Disinhibition Mediated by mGlu(5)-Endocannabinoid Signaling
por: Xiang, Zixiu, et al.
Publicado: (2019)

The functional cooperation of 5-HT(1A) and mGlu4R in HEK-293 cell line
por: Burnat, Grzegorz, et al.
Publicado: (2020)

Regulation and functional consequences of mGlu(4) RNA editing
por: Hofmann, Christopher S., et al.
Publicado: (2021)

Allosteric Modulators for mGlu Receptors
por: Gasparini, F, et al.
Publicado: (2007)

Challenges in the Discovery and Optimization of mGlu(2/4) Heterodimer Positive Allosteric Modulators
por: Fulton, Mark Gallant, et al.
Publicado: (2019)

A GRM7 mutation associated with developmental delay reduces mGlu(7) expression and produces neurological phenotypes
por: Fisher, Nicole M., et al.
Publicado: (2021)

Decreased striatal dopamine in group II metabotropic glutamate receptor (mGlu2/mGlu3) double knockout mice
por: Lane, Tracy A, et al.
Publicado: (2013)

Emotional Impairment and Persistent Upregulation of mGlu(5) Receptor following Morphine Abstinence: Implications of an mGlu(5)-MOPr Interaction
por: Zanos, Panos, et al.
Publicado: (2016)

mGlu1 Receptors Monopolize the Synaptic Control of Cerebellar Purkinje Cells by Epigenetically Down-Regulating mGlu5 Receptors
por: Notartomaso, Serena, et al.
Publicado: (2018)

mGlu5 Receptor Functional Interactions and Addiction
por: Brown, Robyn M., et al.
Publicado: (2012)

Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies
por: Chruścicka-Smaga, Barbara, et al.
Publicado: (2023)

Discovery of “Molecular Switches” within a Series of mGlu(5) Allosteric Ligands Driven by a “Magic Methyl” Effect Affording Both PAMs and NAMs with In Vivo Activity, Derived from an M(1) PAM Chemotype
por: Barbaro, Lisa, et al.
Publicado: (2021)

Exploring the Activation Mechanism of the mGlu5 Transmembrane Domain
por: Lans, Isaias, et al.
Publicado: (2020)

Differential activity of mGlu(7) allosteric modulators provides evidence for mGlu(7/8) heterodimers at hippocampal Schaffer collateral-CA1 synapses
por: Lin, Xin, et al.
Publicado: (2022)

Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats
por: Podkowa, Karolina, et al.
Publicado: (2016)

Withdrawal from Cocaine Self-administration and Yoked Cocaine Delivery Dysregulates Glutamatergic mGlu(5) and NMDA Receptors in the Rat Brain
por: Pomierny-Chamiolo, Lucyna, et al.
Publicado: (2014)

Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology
por: Hammond, Alexis S., et al.
Publicado: (2010)

Function of mGlu1 receptors in the modulation of nociceptive processing in the thalamus()
por: Salt, T.E., et al.
Publicado: (2014)

Structural insights into the activation initiation of full-length mGlu1
por: Zhang, Jinyi, et al.
Publicado: (2020)

mGlu2 mechanism-based interventions to treat alcohol relapse
por: Vengeliene, Valentina, et al.
Publicado: (2022)

The role of thalamic group II mGlu receptors in health and disease
por: Copeland, Caroline S., et al.
Publicado: (2022)

Presynaptic mGlu1 Receptors Control GABA(B) Receptors in an Antagonist-Like Manner in Mouse Cortical GABAergic and Glutamatergic Nerve Endings
por: Vergassola, Matteo, et al.
Publicado: (2018)

Deletion of Metabotropic Glutamate Receptors 2 and 3 (mGlu2 & mGlu3) in Mice Disrupts Sleep and Wheel-Running Activity, and Increases the Sensitivity of the Circadian System to Light
por: Pritchett, David, et al.
Publicado: (2015)

A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding
por: García-Bea, Aintzane, et al.
Publicado: (2017)

Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons
por: Battaglia, Giuseppe, et al.
Publicado: (2009)

Role of the G Protein-Coupled Receptor, mGlu(1), in Melanoma Development
por: Wangari-Talbot, Janet, et al.
Publicado: (2010)

Preclinical and translational studies of fenobam, an mGlu5 NAM, for the treatment of pain
por: Gereau IV, Robert W, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_43vsj1vf1lh6fabuo7kuhg8vcd